Angiolab, Inc. (XKON:251280)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,400.00
0.00 (0.00%)
At close: Feb 13, 2026
Market Cap8.38B -63.8%
Revenue (ttm)702.62M -20.0%
Net Income-1.19B
EPS-1,356.00
Shares Out3.49M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,404
Average Volume4,962
Open2,480.00
Previous Close2,400.00
Day's Range2,350.00 - 2,480.00
52-Week Range2,155.00 - 8,500.00
Beta-0.18
RSI40.18
Earnings Daten/a

About Angiolab

Angiolab, Inc., a biotechnology company, develops medicine with angiogenesis inhibitors for treating angiogenesis-related diseases. Its Phase I products consist of AL101-PSO for psoriasis. The company’s Phase II a clinical trial products include AL101- NASH for the treatment of non-alcoholic steatohepatitis; AL101-OME, for otitis media with effusion; and AL102-PDT for periodontitis. Its Phase II clinical trial products comprise AL101-AMD to treat age related muscular degeneration; and AL101-AOB for the treatment of abnormal obesity. In addition... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Country South Korea
Stock Exchange Korea New Exchange
Ticker Symbol 251280
Full Company Profile

Financial Performance

Financial Statements